RecruitingNot ApplicableNCT06690736
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
Sponsor
Tianjin Medical University
Enrollment
200 participants
Start Date
Mar 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria3
- suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients
- F-FDG PET/CT within two weeks
- signed written consent.
Exclusion Criteria3
- pregnancy
- breastfeeding
- known allergy against Pentixafor
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTCXCR4 PET/CT Imaging
Each subject receive a single intravenous injection of 68Ga/18F-Pentixafor/Pentixather, and undergo PET/CT imaging within the specificed time.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06690736
Related Trials
A Study of Live Tumor Fragments of Surgical Resections
NCT070008641 location
A First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma
NCT074657961 location
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
NCT058791461 location
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT0686327279 locations
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
NCT067543451 location